ADIAL PHARMACEUTICALS INC overview

CHARLOTTESVILLE, VA / ACCESSWIRE / October 5, 2021 / Adial Pharmaceuticals, Inc. (NASDAQ:ADIL;ADILW) ("Adial" or the "Company"), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related disorders, today announced that the Company has been invited to present at the Fall Harvest - Best Ideas from the Buy-Side conference, which is being held virtually this week, October 5 - 8, 2021. William Stilley, Chief Executive Officer...

Acquisition Expands Adial's Portfolio with Drug Candidates for Treatment of Pain and Addiction CHARLOTTESVILLE, VA / ACCESSWIRE / January 26, 2021 / Adial Pharmaceuticals, Inc. (NASDAQ:ADIL; ADILW) ( "Adial" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of treatments for addictions, has closed the acquisition of Purnovate, LLC ("Purnovate"), a pharmaceutical development company focused on developing novel, drug candidates for non-opioid pain reduction,...

CHARLOTTESVILLE, VA / ACCESSWIRE / January 11, 2021 / Adial Pharmaceuticals, Inc. (NASDAQ:ADIL; ADILW) ( "Adial" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of treatments for addictions, today announced that William Stilley, Chief Executive Officer of Adial Pharmaceuticals has been invited to present a Company overview at the 23rd Annual ICR Conference on Thursday, January 14, 2021 at 3:15pm-3:55pm Eastern Time. A live webcast of the Company's...

CHARLOTTESVILLE, VA / ACCESSWIRE / January 11, 2020 / Adial Pharmaceuticals, Inc. (NASDAQ:ADIL; ADILW) , a clinical-stage biopharmaceutical company focused on the development of treatments for addictions, today announced receipt of a Notice of Allowance for its third U.S. patent relating to the use of AD04 for the treatment of opioid use disorder (OUD). The patent covers the use of the Company's lead product, AD04, as a treatment of Opioid Use Disorder in patients with a specific genetic...

ONWARD™ Trial Remains on Track to be Fully Enrolled During Q2 2021 CHARLOTTESVILLE, VA / ACCESSWIRE / December 17, 2020 / Adial Pharmaceuticals, Inc. (NASDAQ:ADIL; ADILW) , a clinical-stage biopharmaceutical company focused on the development of treatments for addictions, today announced it has reached the 35% enrollment target in the Company's landmark ONWARD™ Phase 3 pivotal trial in Europe. ONWARD™ is investigating the efficacy and safety of Adial's lead drug candidate, AD04, as a...

CHARLOTTESVILLE, VA / ACCESSWIRE / December 15, 2020 / Adial Pharmaceuticals, Inc. (NASDAQ:ADIL; ADILW) , a clinical-stage biopharmaceutical company focused on the development of treatments for addiction, today announced the appointment of Dr. Jack Reich as Head of Regulatory, effective December 14, 2020. As part of his transition to Company management, Dr. Reich stepped down from the Board of Directors to serve in his new full-time role. Dr. Jack Reich's career spans over 35 years in the...